OncoPEP's Series A - II Round

OncoPEP raised a round of funding on March 19, 2012.

ONCoPEP is developing targeted immunotherapies to prevent the progression of cancer, prolong survival and restore the quality of life of patients. ONCoPEP's lead program, PVX-410, is a multi-peptide t…

Articles about OncoPEP's Series A - II Round: